<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-91179</identifier>
<setSpec>0304-5013</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">First three cases in Spain of term pregnancy after treatment of uterine fibroid with non-invasive MRgFUS surgery</dc:title>
<dc:description xml:lang="en">Magnetic resonance-guided focused ultrasound surgery (MRgFUS) is a non-invasive surgical technique based on thermal coagulative necrosis of tissue by focused ultrasound guided by magnetic resonance. This fairly recent technique was approved by the American Food and Drug Administration in 2004 and by the European Union in 2006 for the treatment of uterine fibroids. In 2010 MRgFUS was approved by the European Union (CE label) for the treatment of adenomyosis and is being developed for the non-invasive treatment of other tumoral diseases, mainly in oncology. We present the first three cases of pregnancy achieved at the Instituto Cartuja, the only site in Spain with MRgFUS technology. We conclude that MRgFUS is a safe, reliable and effective technique for the treatment of uterine fibroids, even in women with a desire to preserve fertility (AU)</dc:description>
<dc:creator>García Laffitte, Elena</dc:creator>
<dc:creator>Millán Cantero, Helena</dc:creator>
<dc:creator>Suárez Ramos, Jerónimo</dc:creator>
<dc:creator>Gómez González, Emilio</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La tecnología MRgFUS (magnetic resonance guided focused ultrasound surgery) es una técnica de cirugía no invasiva basada en la necrosis coagulativa térmica del tejido mediante la concentración &#151;focalización&#151; de ultrasonidos guiados por resonancia magnética. Es una novedosa tecnología aprobada por la Food and Drug Administration norteamericana en 2004 y por la Unión Europea (marca CE) en 2006 para el tratamiento de los miomas uterinos. En 2010 recibió la aprobación CE para el tratamiento de la adenomiosis y se está desarrollando para el tratamiento no invasivo de otras patologías tumorales, principalmente en oncología. Presentamos los primeros 3 casos de gestaciones tras tratamiento de miomas conseguidos en Instituto Cartuja, único centro en España con la tecnología MRgFUS, concluyendo que se trata de una técnica fiable, segura y efectiva para el tratamiento de fibromas uterinos incluso en mujeres con deseo genésico (AU)</dc:description>
<dc:source>Prog. obstet. ginecol. (Ed. impr.);54(11): 601-604, nov. 2011. tab, ilus</dc:source>
<dc:identifier>ibc-91179</dc:identifier>
<dc:title xml:lang="es">Primeros 3 casos en España de gestación a término tras tratamiento de miomas mediante cirugía no invasiva MRgFUS</dc:title>
<dc:subject>^d9406^s29166</dc:subject>
<dc:subject>^d22261</dc:subject>
<dc:subject>^d5486^s22016</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d4794^s22016</dc:subject>
<dc:subject>^d5486^s22032</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d5486^s29166</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d9406^s22016</dc:subject>
<dc:subject>^d22935^s22045</dc:subject>
<dc:subject>^d9406^s22032</dc:subject>
<dc:subject>^d5486^s22009</dc:subject>
<dc:subject>^d9406^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201111</dc:date>
</metadata>
</record>
</ibecs-document>
